Abstract: Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: wherein, in Formula I, —R1 is a C1-C3 alkoxy, ?O, or —OH, and —R2 is a 5- or 6-membered heteroaryl including 1 to 2 hetero atoms selected from nitrogen and oxygen, wherein a carbon of the 5- or 6-memberedheteroaryl is optionally substituted with a C1-C3 alkyl a C1-C3 alkoxy, or hydroxy.

Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

Abstract: Provided is an apparatus and method for calculating a correction factor, the apparatus including: a counter configured to acquire first data indicating a counted value of a first radiation source according to an activity and an energy window width, and to acquire second data indicating a coincidence value of a second radiation source according to an activity and an energy window width; and a calculator configured to calculate a correction factor for correcting a difference of the coincidence value of the second radiation source having occurred in response to a single gamma photon emission of the first radiation source, based on the first data and the second data.

Abstract: Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: wherein, in Formula I, —R1 is a C1-C3 alkoxy, ?O, or —OH, and —R2 is a 5- or 6-membered heteroaryl including 1 to 2 hetero atoms selected from nitrogen and oxygen, wherein a carbon of the 5- or 6-memberedheteroaryl is optionally substituted with a C1-C3 alkyl a C1-C3 alkoxy, or hydroxy.

Abstract: Provided is a polyhedral-shaped radiation counter which measures a radiation level of a radioactive material, in which sensor modules configured to measure the radiation level are disposed at vertexes of a polyhedral shape, respectively, and the sensor modules are connected to each other by rod-shaped frame members disposed in edge positions of the polyhedral shape and face parts of the polyhedral shape form an open space.

Abstract: Provided are a method of enhancing radiation sensitivity by using miR-499b-5p and a method of treating a radiation resistant cancer including administering miR-499b-5p.

Abstract: The present invention provides a pharmaceutical composition for suppressing angiogenesis, containing heat shock protein 27 (HSP27) or a nucleic acid encoding HSP27. In addition, the present invention provides a pharmaceutical composition for treating cancer, containing HSP27 or a nucleic acid encoding HSP27. Additionally, the present invention provides a method of suppressing the in vitro growth of endothelial cells using HSP27. Further, the present invention provides a method of screening an active material for suppressing angiogenesis or an active material for treating cancer, comprising the following steps: processing endothelial cell lines into samples, respectively; measuring the content of HSP27 in an endothelial cell line; and selecting the sample in which the content of HSP27 in an endothelial cell line is increased compared with a control group.

Abstract: An apparatus and method for determining an optimal energy window for optimal positron emission tomography (PET) is disclosed. An optimal energy window determining apparatus may include a data corrector configured to correct data measured from an image quality phantom, an image quality measurer configured to measure an image quality for the corrected data, and an optimal energy window determiner configured to determine the optimal energy window based on the measured image quality. The data corrector may correct the measured data based on a difference between sensitivities measured using different radiopharmaceuticals in at least one energy window.

Abstract: Provided are apparatuses and methods of resampling event data for quantitative improvement of a PET image, which acquire a quantitatively-improved new PET image by analyzing a storage format of list data prior to conversion into the PET image and nonparametrically resampling event data from the list data based on the analysis results to improve noise and statistical characteristics thereof. The quantitatively improved new PET image may be acquired by analyzing a storage format of list data constituting the PET image and nonparametrically resampling event data to improve noise and statistical characteristics thereof.

Abstract: An apparatus and method for determining an optimal energy window for optimal positron emission tomography (PET) is disclosed. An optimal energy window determining apparatus may include a data corrector configured to correct data measured from an image quality phantom, an image quality measurer configured to measure an image quality for the corrected data, and an optimal energy window determiner configured to determine the optimal energy window based on the measured image quality. The data corrector may correct the measured data based on a difference between sensitivities measured using different radiopharmaceuticals in at least one energy window.

Abstract: A radioactive isotope liquid targeting apparatus having a functional thermosiphon internal flow channel according to the present invention includes a cavity member having a cavity for accommodating a concentrate for a nuclear reaction. The cavity member includes: a front thin film having a front opening and a rear opening; a front cooling member which is coupled to the cavity member; a thermosiphon induction member which is connected to the rear opening and which has a thermosiphon flow channel connected to the cavity so as to enable the concentrate accommodated in the cavity to flow by means of a thermosiphon phenomenon; and a rear cooling member which is coupled to the rear surface of the thermosiphon induction member and which has a cooling water supply space.

Abstract: Provided are a method of enhancing radiation sensitivity by using miR-499b-5p and a method of treating a radiation resistant cancer including administering miR-499b-5p.

Abstract: A multi-leaf collimator device for radiotherapy, including: a frame that has a box shape and has through-holes formed in top and bottom surfaces thereof; a plurality of collimators that are received in the frame, wherein each of the collimators includes a rack gear formed on the top surface of the collimator, the collimators are symmetrically arranged in a left-right direction about a central portion of the frame, and are slidably provided on the frame; and a motion driving unit that includes a pinion gear that is formed to be detachable from the rack gear formed on the top surface of the collimator, and is provided on the frame to move the pinion gear in a front-back direction of the frame and an up-down direction of the frame.

Abstract: The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection.

Abstract: A portable phantom device according to the present invention is a phantom device which is detachably installed in a bird cage that is coupled to an irradiator, and includes a body provided with an accommodation space having a cylindrical shape and a top of which is open so as to accommodate water, a horizontality adjustment maintaining portion which is detachably coupled to a side wall of the body; and a sensor holding portion which is installed on the side wall of the body so as not to interfere with the horizontality adjustment maintaining portion, so that a sensor for measuring the amount of radiation that is incident on the accommodation space may be inserted from the outside of the body and accommodated in the body (Representative drawing: FIG.

Abstract: The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27.

Abstract: Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).

Abstract: The present disclosure relates to a deacetylation hydrolase of a hyaluronic acid a hyaluronic acid deacetylated by same and a derivative thereof. The deacetylated hyaluronic acid and the derivative thereof have the following characteristic: a delayed initial decomposition rate on a living body; minimized decrease of molecular weight and viscosity; accelerated gelation due to a lower gelation temperature than the gelation temperature for a non-deacetylated hyaluronic acid; and an hMSC survival rate that is hardly affected by increased concentration of the deacetylated hyaluronic acid and the derivative thereof in a culture medium. As a result, the deacetylated hyaluronic acid and the derivative thereof can be useful as a bioingredient such a delivery system for a cell, gene, drug, and the like, or a support for tissue engineering, etc.

Abstract: Provided are a method of producing a porous chitosan scaffold, the method including: providing an aqueous acidic solution having chitosan and a solvent which does not dissolve the chitosan; and freeze-drying the aqueous acidic solution, wherein the solvent is selected from the group consisting of a C3-C8 aliphatic alcohol having one hydroxy group, ethylene glycol monoethylether, ethylene glycol monobutylether, dioxane, tetrahydrofuran, dimethylcarbonate, acetone and acetonitrile, and a chitosan scaffold produced using the method.

Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.